This is a working overview of melanocortin receptor, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
Activity is attributed to agonism at melanocortin receptors, particularly MC1R and MC4R. Activation of MC1R on melanocytes increases melanin synthesis, which underlies the reported tanning effect. MC4R engagement in the central nervous system is linked to appetite suppression and to effects on sexual arousal reported in early clinical studies. Those studies were small and were not designed to establish efficacy or long-term safety. Receptor selectivity among the melanocortin subtypes is not absolute, which complicates attribution of any effect to a single pathway.
Regulatory treatment varies between countries. Several national medicines agencies have classified the peptide as unapproved, and customs authorities in some jurisdictions seize shipments on that basis. A few jurisdictions channel supply through prescription-only frameworks that do not list the substance by name. Because the material circulates mainly through online vendors, composition and purity are rarely verified before sale. Surveys of unapproved peptide products have reported labels that did not match measured content in a substantial fraction of samples.
Melanotan-2 is a synthetic peptide designed as an analog of alpha-melanocyte-stimulating hormone, a signaling molecule produced in the pituitary and skin. Its structure is a linear chain of seven amino acids that folds into a ring through an internal lactam bridge joining two side chains. The compound is sometimes written as MT-II or MEL-2 in informal and commercial contexts. It belongs to the melanocortin peptide family, a group of short signaling molecules that share a conserved core sequence recognized by melanocortin receptors.
Two structural changes distinguish the synthetic peptide from the natural hormone. A norleucine residue replaces methionine at one position, and a D-configured phenylalanine replaces the natural L-form at another. Both substitutions slow enzymatic breakdown, which extends the molecule's persistence relative to the parent hormone. The lactam bridge further constrains the backbone into a stable conformation. These features are standard design strategies in peptide chemistry and are not unique to this compound; they appear across many research peptides built for improved stability.
The compound was developed in the late 1980s and early 1990s by academic researchers investigating melanocortin signaling and pigmentation. Early work explored whether synthetic analogs could reproduce effects of the natural hormone under controlled conditions. The molecule never advanced through the full regulatory pathway required for approval as a medicine. From the mid-2000s onward it appeared in unregulated consumer markets, often distributed through informal channels. That gap between research origins and commercial availability shapes how the compound is discussed today.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Analogue of alpha-melanocyte-stimulating hormone |
| Common synonyms | MT-II; melanotan 2 | No internationally accepted non-proprietary name |
| Typical presentation | Lyophilised powder in a sealed vial | Often supplied alongside a separate diluent |
| Regulatory status | Unapproved therapeutic substance | Customs seizure reported in several jurisdictions |
| Reported route in use | Subcutaneous injection | Self-administered outside clinical settings |
Melanotan II is a synthetic cyclic heptapeptide analog derived from the core sequence of alpha-melanocyte-stimulating hormone. Researchers at the University of Arizona synthesized it during the 1980s while studying pigmentation and appetite signaling. The compound is not an approved medicine in any major jurisdiction and appears mainly in laboratory and research-chemical settings. Its structure incorporates a lactam bridge between side chains, which constrains the ring and slows enzymatic breakdown relative to the natural hormone.
Melanotan II binds several melanocortin receptor subtypes rather than a single target. MC1R on melanocytes drives melanin synthesis, while MC3R and MC4R participate in energy balance, appetite, and sexual response pathways. This lack of selectivity explains why reported effects extend beyond skin darkening. Substitutions at positions four and seven, including norleucine and D-phenylalanine, increase potency and resistance to peptidases. Understanding which receptor mediates which effect remains an active area of investigation.
Published human data come mostly from small, short studies rather than large controlled trials. Reported outcomes include increased skin pigmentation and, in some reports, effects on appetite and libido, but sample sizes are small and follow-up is limited. Whether long-term use produces durable pigment changes or adverse effects is not established. Because products sold outside pharmacies are not standardized, the actual content of any given vial is often unknown. Independent testing of such material is uncommon.
Receptor binding at MC1R on melanocytes raises intracellular cyclic AMP and increases expression of tyrosinase and related enzymes. The downstream result is greater synthesis of eumelanin, the dark pigment, without ultraviolet exposure acting as the trigger. The compound is not selective, however, and also engages MC3R, MC4R and MC5R, which are expressed in the central nervous system and elsewhere. That lack of selectivity is the explanation usually offered for effects reported outside pigmentation, including appetite suppression and nausea. Selectivity remains a central theme in comparative studies of related peptides.
Human data remain limited and mostly short-term. Reports describe small trials and observational accounts rather than large controlled studies, so questions about dose-response relationships and long-term effects on melanocytes stay open. Whether repeated exposure alters naevus behaviour is not settled in the published record. Researchers also note that self-administered use outside clinical settings makes actual exposure difficult to quantify. Statements about efficacy and safety should therefore be read as preliminary rather than established.
In his introduction to the 1895 edition of Karl Marx's The Class Struggles in France, Engels attempted to resolve the division between gradualist reformist and revolutionary socialists in the Marxist movement by declaring that he was in favour of short-term tactics of electoral politics that included gradualist and evolutionary socialist policies while maintaining his belief that revolutionary seizure of power by the proletariat should remain a key goal of the socialist movement. In spite of this attempt by Engels to merge gradualism and revolution, his effort only diluted the distinction of gradualism and revolution and had the effect of strengthening the position of the revisionists. Engels' statements in the French newspaper Le Figaro in which he argued that "revolution" and the "so-called socialist society" were not fixed concepts, but rather constantly changing social phenomena and said that this made "us [socialists] all evolutionists", increased the public perception that Engels was gravitating towards evolutionary socialism. Engels also wrote that it would be "suicidal" to talk about a revolutionary seizure of power at a time when the historical circumstances favoured a parliamentary road to power which he predicted could happen "as early as 1898." Engels' stance of openly accepting gradualist, evolutionary and parliamentary tactics while claiming that the historical circumstances did not favour revolution caused confusion among political commentators and the public.
=== FORTUNE, Modern Healthcare and Press Ganey awards === Southern Ohio Medical Center has been recognized as one of FORTUNE Magazine’s Best Places to Work in America for six straight years. In 2013, it came in 29th on the list with FORTUNE noting: “Employees are proud to work for a medical provider that has won numerous awards for patient care, a fact that's reflected in its average tenure. Nearly 20% of the staff has worked there for more than 20 years.” SOMC was recognized on the FORTUNE list again in 2014 (coming in 18th) and 2015 (coming in 44th). In the 2015 survey, 93% of SOMC employees described their workplace as "a great place to work." Modern Healthcare Magazine also recognized SOMC as one of the nation's best healthcare employers in 2010, 2011 and 2012. In 2012, Southern Ohio Medical Center was one of only 13 Press Ganey clients in the nation to be chosen as a Distinctive Workplace Award winner. The award was given to organizations that reached, and sustained, the 95th percentile in employee satisfaction – SOMC was at the 99th percentile.
=== Relative versus absolute measurement === Vacuum is measured in units of pressure, typically as a subtraction relative to ambient atmospheric pressure on Earth. But the amount of relative measurable vacuum varies with local conditions. On the surface of Venus, where ground-level atmospheric pressure is much higher than on Earth, much higher relative vacuum readings would be possible. On the surface of the Moon with almost no atmosphere, it would be extremely difficult to create a measurable vacuum relative to the local environment. Similarly, much higher than normal relative vacuum readings are possible deep in the Earth's ocean. A submarine maintaining an internal pressure of 1 atmosphere submerged to a depth of 10 atmospheres (98 metres; a 9.8-metre column of seawater has the equivalent weight of 1 atm) is effectively a vacuum chamber keeping out the crushing exterior water pressures, though the 1 atm inside the submarine would not normally be considered a vacuum. Therefore, to properly understand the following discussions of vacuum measurement, it is important that the reader assumes the relative measurements are being done on Earth at sea level, at exactly 1 atmosphere of ambient atmospheric pressure.
Sources: en.wikipedia.org
=== Research === Baeocystin (PLZ-1019) – non-hallucinogenic serotonin 5-HT2A receptor agonist, other actions Norpsilocin (PLZ-1017) – non-hallucinogenic serotonin 5-HT2A receptor agonist, other actions Roluperidone (CYR-101, MIN-101, MT-210) – serotonin 5-HT2A, sigma σ2, and α1A-adrenergic receptor antagonist Squalamine (ENT-01; Enterin-01; kenterin) – various actions
=== Antibacterial Activity === Guanacastepene A has been identified as a potent active ingredient against a wide range of pathogens, with a particular focus on its efficacy against highly resistant clinical isolates. In screening tests, such as the agar diffusion method and the microbroth dilution method, the susceptibility of microorganisms to the active compound Guanacastepene A was determined. In the agar diffusion method, efficacy was assessed by the formation of growth inhibition zones on the solid medium of the test plates. The results indicate that Guanacastepene A exhibits moderate activity against Gram-positive bacteria and poor to low activity against Gram-negative bacteria. In another agar diffusion test, Guanacastepene A produced an inhibition zone against MRSA; particularly noteworthy is its activity against vancomycin-resistant enterococci (VRE/VREF), against which conventional antibiotics such as vancomycin are ineffective. Using the microbroth dilution method, a minimum inhibitory concentration (MIC) of 62.5 µg/ml was determined for a specific test strain (E. coli imp). In this regard, mechanistic studies on Escherichia coli demonstrate that Guanacastepene A has a bactericidal effect. Thus, the active compound not only inhibits growth (bacteriostatic) but actually leads to the death of bacterial cells.
=== NutraSweet Company === In 1985, Monsanto bought G.D. Searle, and the aspartame business became a separate Monsanto subsidiary, NutraSweet. In March 2000, Monsanto sold it to J.W. Childs Associates Equity Partners II L.P. European use patents on aspartame expired beginning in 1987, with the US patent following suit in 1992.
Sources: en.wikipedia.org
=== Video === introduction to NMR and MRI Richard Ernst, NL – Developer of multidimensional NMR techniques Freeview video provided by the Vega Science Trust. 'An Interview with Kurt Wuthrich' Freeview video by the Vega Science Trust (Wüthrich was awarded a Nobel Prize in Chemistry in 2002 "for his development of nuclear magnetic resonance spectroscopy for determining the three-dimensional structure of biological macromolecules in solution"). The Nobel Prize Winner - Documentary about Richard R. Ernst by Lukas Schwarzenbacher and Susanne Schmid (Swiss German with English subtitles) Other Qian, C.; Pines, A.; Martin, R. W. (September 2007). "Off Magic Angle Spinning". Journal of Magnetic Resonance. 188 (1): 183–189. Bibcode:2007JMagR.188..183Q. doi:10.1016/j.jmr.2007.06.006. PMID 17638585. Spotlight on nuclear magnetic resonance: a timeless technique
Neurosteroids such as dehydroepiandrosterone (DHEA) and allopregnanolone, which modulate neurotransmitter receptors in the brain. Bile acids such as taurocholic acid, which aid in lipid digestion and absorption in the intestine. Aminosteroid neuromuscular blocking agents (synthetic), such as pancuronium bromide, used in anesthesia to induce muscle relaxation. Steroidal antiandrogens (synthetic), such as cyproterone acetate, which block androgen receptors in hormone therapy. Steroidogenesis inhibitors (exogenous), such as alfatradiol, which suppress steroid synthesis for therapeutic purposes. Membrane sterols such as cholesterol (essential for cell membrane fluidity), ergosterol (a fungal membrane component), and various phytosterols (plant-derived sterols with cholesterol-lowering effects). Toxins such as steroidal saponins (plant defense compounds) and cardenolides/cardiac glycosides (which affect heart function). Steroids with an open-ring structure, known as secosteroids, include:
=== Before modelling === Most tertiary structure modelling methods, such as Rosetta, are optimized for modelling the tertiary structure of single protein domains. A step called domain parsing, or domain boundary prediction, is usually done first to split a protein into potential structural domains. As with the rest of tertiary structure prediction, this can be done comparatively from known structures or ab initio with the sequence only (usually by machine learning, assisted by covariation). The structures for individual domains are docked together in a process called domain assembly to form the final tertiary structure.
The result was a disaster, with 140 men killed and over 1,000 captured. The siege of Ladysmith lasted months. Meanwhile, to the north-west at Mafeking, on the border with Transvaal, Colonel Robert Baden-Powell had raised two regiments of local forces amounting to about 1,200 men in order to attack and create diversions if things went wrong further south. As a railway junction, Mafeking provided good supply facilities and was the obvious place for Baden-Powell to fortify in readiness for such attacks. However, instead of being the aggressor, Baden-Powell was forced to defend Mafeking when 6,000 Boer, commanded by Piet Cronjé, attempted a determined assault. This quickly subsided into a desultory affair, with the Boers prepared to starve the stronghold into submission. So, on 13 October, the 217-day siege of Mafeking began. Lastly, over 360 kilometres (220 mi) to the south of Mafeking lay the diamond mining city of Kimberley, which was also subjected to a siege. Although not militarily significant, it represented an enclave of British imperialism on the borders of the Orange Free State and was hence an important Boer objective. In early November, about 7,500 Boer began their siege, again content to starve the town into submission. Despite Boer shelling, the 40,000 inhabitants, of which only 5,000 were armed, were under little threat, because the town was well-stocked with provisions. The garrison was commanded by Lieutenant Colonel Robert Kekewich, although Rhodes was also a prominent figure in the town's defences.
Sources: en.wikipedia.org
No. No major regulatory agency has granted a marketing authorisation for melanotan II as a medicine. Products sold under this name are generally presented as laboratory reagents and are not subject to the batch-release testing applied to approved drugs.
It was developed in the 1980s by researchers investigating analogues of alpha-melanocyte-stimulating hormone for pigmentation and related endpoints. Early work included small human studies during the 1990s. Development did not progress to licensing, and the compound remained a research and grey-market item.
Peptides are prone to truncation, oxidation and aggregation during synthesis and handling. Without independent testing, a buyer cannot confirm the identity or the content of a vial. Analytical surveys of unapproved peptide products have repeatedly found discrepancies between label claims and measured composition.
It is a synthetic seven-amino-acid peptide modeled on alpha-melanocyte-stimulating hormone. It carries two non-natural substitutions and a cyclic bridge that increase its stability relative to the natural hormone. It circulates as a research chemical and is not an approved medicine.